Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 14/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12813743 | 0.76 | KDM4E (0.53) | CYP11B1CYP11B2CNR2PIM1PIM3 | |
| SCHEMBL26711595 | 0.75 | TRPV1 (0.42) | CNR2HRH3 | |
| SCHEMBL27344460 | 0.70 | PIM1 (0.39) | CYP11B1CYP11B2CNR2PIM1PIM3 | |
| SCHEMBL17581373 | 0.69 | CNR2 (0.41) | CNR2DPP4HRH3 | |
| SCHEMBL31453966 | 0.68 | CYP11B1 (0.38) | CYP11B1CYP11B2CNR2PIM1PIM3 | |
| SCHEMBL16742786 | 0.68 | NSD2 (0.36) | CYP11B1CYP11B2CNR2NSD2DPP4 | |
| SCHEMBL38656893 | 0.67 | CNR2 (0.40) | CNR2DPP4HRH3 | |
| SCHEMBL38656894 | 0.67 | CNR2 (0.40) | CNR2DPP4HRH3 | |
| SCHEMBL3930492 | 0.67 | DPP4 (0.47) | CNR2DPP4 | |
| SCHEMBL12615343 | 0.66 | KDM4E (0.60) | CYP11B1CYP11B2CNR2PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217989-A1 | Heteroaryl Fluoroalkenes As DGK Inhibitors | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| US-20240217989-A1 | Heteroaryl Fluoroalkenes As DGK Inhibitors | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| US-20240217989-A1 | Heteroaryl Fluoroalkenes As DGK Inhibitors | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| WO-2024108100-A1 | HETEROARYL FLUOROALKENES AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024108100-A1 | HETEROARYL FLUOROALKENES AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2024-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217989-A1 | Heteroaryl Fluoroalkenes As DGK Inhibitors | DGKA, DGKG, DGKK | CYP11B1 3774/4885CYP11B2 3739/4885CNR2 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.